Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy

Boaz Wong, Anabel Bergeron, Glib Maznyi, K. W. Ng, Anna Jirovec, Harsimrat Kaur Birdi, Daniel Serrano, Marcus M. Spinelli, Max Thomson, Zaid Taha, Akram Alwithenani, Andrew Chen, Ian A.J. Lorimer, Barbara C. Vanderhyden, Rozanne Arulanandam, Jean‐Simon Diallo